Market Capitalization

Nakamoto Inc. acquires Bitcoin Magazine's parent and a key investment firm in an all-stock deal, raising questions about market influence and shareholder value.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

After a soft 2025, Graphic Packaging's CEO faces investors. With the stock lagging, all eyes are on whether its green strategy can deliver growth.

A record-breaking drone and air taxi display at the Spring Festival Gala was more than a show; it was a bold statement on China's low-altitude economy.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

A new partnership signals a major shift in the art market, placing scientific conservation at the heart of determining an asset's long-term value.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

Legrand's plan to repurchase 250,000 shares goes beyond pure financials, signaling a strategic investment in its workforce amid a competitive market.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Cohen & Co.-backed SPAC joins the hunt for a merger target, highlighting a renewed investor appetite for blank check companies in a maturing market.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

VisionWave Holdings is leveraging a breakthrough in non-line-of-sight detection to compete for a piece of the Pentagon's new $13.4 billion autonomy budget.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

Proem Acquisition Corp I launches a $130M IPO, led by tech IPO guru Imran Khan. But can it succeed in a revived, yet risk-laden, SPAC landscape?

As a Fed study confirms the 'harvest now, decrypt later' threat is active, Dr. Joseph Kearney joins QRL to spearhead a quantum-safe future for blockchain.

Indoor ag firm Local Bounti faces a potential NYSE delisting for the second time, highlighting severe financial pressures in the high-tech farming sector.